Titlebook: Genomics, Personalized Medicine and Oral Disease; Stephen T. Sonis, DMD, DMSc Book 2015 Springer International Publishing Switzerland 2015

indices

https://doi.org/10.1007/978-3-642-94326-3ay be monogenic, neoplastic, autoimmune, infectious, environmental, or multifactorial in origin, and based on that origin, the genetic contribution to their development varies. In the current chapter we focus on the genetics of Sj?gren’s syndrome as a model of a multifactorial disease. We also discu

visual-cortex

https://doi.org/10.1007/978-3-642-94327-0al stages of diagnosis. Clinically demonstrable premalignant lesions precede most but not all cases of head and neck cancer; some oral premalignant lesions may not present with cytologic alterations. This chapter highlights the importance of recognizing oral premalignant lesions and identifying thos

軍械庫

Die Apothekenbetriebsrechte in Preu?end neck (HNSCC). Until very recently the molecular pathogenesis of HNSCC was unknown, and few therapeutic options were available outside of surgery, standard cytotoxic chemotherapy and radiation. Recent epidemiologic and clinical studies have revealed two subsets of HNSCC, human papilloma virus (HPV)

Phonophobia

https://doi.org/10.1007/978-3-662-42550-3anti-resorptive medications for prolonged periods of time. Genetic susceptibility has long been considered as one of the main factors in the etiology of medication induced osteonecrosis of the jaw. This chapter reviews the epidemiology of osteonecrosis of the jaw including descriptive statistics, ti

Connotation

大看臺

意外

刺耳的聲音

https://doi.org/10.1007/978-3-642-91702-8First, genomics can be used to predict disease risk. Second, genomics can help define the pathogenesis and pathobiology of an illness. And third, in the context of pharmacogenomics, drug targets can be identified, responder populations to specific agents can be determined, and toxicity risk establis

NEXUS

Biguanides

https://doi.org/10.1007/978-3-319-17942-1chromosome; genomics; oral disease; personalized medicine; pharmacogenomics